Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

2,361

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Acne Vulgaris
Interventions
DRUG

Dapsone 5.0% Gel (SEEGPharm)

Topical Gel

OTHER

Placebo

Topical Gel

DRUG

Dapsone 5.0% Gel (Allergan)

Topical Gel

Trial Locations (36)

10012

Catawba Clinical Research, New York

13760

Catawba Clinical Research, Endwell

15241

Catawba Clinical Research, Upper Saint Clair

18974

Catawba Clinical Research, Warminster

19046

Catawba Clinical Research, Jenkintown

23507

Catawba Clinical Research, Norfolk

27262

Catawba Clinical Research, High Point

28405

Catawba Clinical Research, Wilmington

31406

Catawba Clinical Research, Savannah

33016

Catawba Clinical Research, Hialeah

33027

Catawba Clinical Research, Miramar

33175

Catawba Clinical Research, Miami

33486

Catawba Clinical Research, Boca Raton

33511

Catawba Clinical Research, Brandon

33609

Catawba Clinical Research, South Tampa

33618

Catawba Clinical Research, Tampa

37215

Catawba Clinical Research, Nashville

45246

Catawba Clinical Research, Cincinnati

68134

Catawba Clinical Research, Omaha

68701

Catawba Clinical Research, Norfolk

70130

Catawba Clinical Research, New Orleans

75149

Catawba Clinical Research, Mesquite

78746

Catawba Clinical Research, Austin

79902

Catawba Clinical Research, El Paso

89106

Catawba Clinical Research, Las Vegas

89109

Catawba Clinical Research, Las Vegas

89119

Catawba Clinical Research, Las Vegas

90017

Catawba Clinical Research, Los Angeles

90036

Catawba Clinical Research, Los Angeles

91403

Catawba Clinical Research, Sherman Oaks

91436

Catawba Clinical Research, Encino

91942

Catawba Clinical Research, La Mesa

92592

Catawba Clinical Research, Temecula

92835

Catawba Clinical Research, Fullerton

97030

Catawba Clinical Research, Richland

Unknown

Catawba Clinical Research, Belize City

All Listed Sponsors
lead

Seegpharm S.A.

INDUSTRY

NCT02865005 - Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter